Novo Nordisk on Friday revealed disappointing results in a late-stage trial for its experimental next-generation obesity drug ...
The FDA has expanded the approval of Eli Lilly’s obesity medication Zepbound to include treating moderate to severe ...
The US FDA approved Eli Lilly's Zepbound as the first ever medication for obstructive sleep apnea for patients who also have ...
New York Daily News on MSN10d
Weight loss drugs credited with decline in U.S. obesity ratesNotable decrease seen in South, which had highest prescription rates for Ozempic, Wegovy and other weight loss meds ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback